Building Your Care Team
At a Glance
People with CLN12 disease benefit from a coordinated team led by a movement-disorder neurologist, with genetics, psychiatry, rehabilitation, primary care, and social-work support added as needed. Bring the ATP13A2 genetic report, imaging, and symptom and medication records to visits.
Because ATP13A2-related disease involves the brain, the muscles, and even emotional well-being, no single doctor can manage it alone. Building a coordinated care team is a vital step in navigating the “clinical continuum” of this rare condition [1][2].
Rather than seeing isolated specialists, your goal is to create an interdisciplinary team—a group of experts who communicate with one another to ensure your treatment for movement doesn’t conflict with your treatment for mood or thinking [2][3].
Your Core Medical Team
For an ultra-rare neurogenetic condition, your team should ideally be anchored by specialists who see these types of complex disorders regularly.
- Movement Disorder Neurologist: This is a neurologist with extra training in conditions like parkinsonism and dystonia. They are the lead coordinator for managing tremors, stiffness, and gait [4].
- Neurogeneticist or Clinical Geneticist: These experts help interpret your specific ATP13A2 variants and provide genetic counseling for your family [3][5].
- Neuropsychiatrist or Psychiatrist: Because psychiatric symptoms like hallucinations or behavioral changes can be early signs of this condition, having a psychiatrist who works closely with your neurologist is highly recommended [2][6].
- Rehabilitation Specialists: This includes Physical Therapists (PT), Occupational Therapists (OT), and Speech-Language Pathologists (SLP). They focus on the practicalities of daily life—walking safely, using your hands, and swallowing [7][8].
- Primary Care Provider and Social Worker: Provide foundational health management, help navigate disability support, access respite care, and manage insurance.
Specialized Support as Needed
Depending on your specific symptoms, you may also need to add “consulting” specialists to your team:
- Ophthalmologist: To monitor for the eye-movement issues (gaze palsy) common in Kufor-Rakeb [2].
- Epileptologist: A neurologist who specializes in seizures, if they become part of your clinical picture [9].
- Registered Dietitian or Gastroenterologist: If swallowing difficulties make it hard to maintain a healthy weight or nutrition [10].
- Palliative Care Clinician: To help with advance-care planning and managing quality of life.
Preparing for Your First Specialist Visit
When you see a specialist for a rare disease, you are often the “expert” on your own history. Being organized helps the doctor focus on the most important details. Bring the following to every first appointment:
- The Genetic Report: This is the most important document. It lists the exact mutations in your ATP13A2 gene [11].
- Imaging Records: If you have had an MRI, bring the radiology report and arrange access to the original images through the hospital portal or an accepted digital medium.
- A Shared Symptom/Medication Tracker: Write down which symptoms appeared first, the order in which they developed, and a shared list of current medications and side effects.
How to Find the Right Expertise
Finding a doctor who has seen another case of ATP13A2 may be difficult because the condition is so rare. Instead of looking for a “CLN12 doctor,” look for specialists at Academic Medical Centers or Centers of Excellence for related groups of diseases:
- NCL Clinics: Centers that specialize in Neuronal Ceroid Lipofuscinoses.
- HSP Centers: Clinics focused on Hereditary Spastic Paraplegia.
- NBIA Centers: Centers for Neurodegeneration with Brain Iron Accumulation [12].
However, it is important to explicitly ask if the clinicians have experience with the ATP13A2 spectrum, as clinical features like iron accumulation are not universal. Utilize reputable rare-disease directories or international registry contacts to find specialized care rather than assuming every center in these categories is appropriate. Affiliation with a research university often means your doctor has access to the latest scientific literature and may be connected to international registries that track patients with ATP13A2 mutations [11]. Establishing a “home base” at one of these centers can help ensure your care is proactive rather than reactive.
Common questions in this guide
Which specialists should be part of a CLN12 care team?
What should I bring to my first ATP13A2 specialist appointment?
How can I find a doctor with experience in CLN12 disease?
Who coordinates care when CLN12 affects movement, mood, and thinking?
When should the CLN12 care team be contacted between visits?
Why is genetic counseling part of CLN12 care?
Get notified when new evidence is published on CLN12 disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
Estrada-Cuzcano A, Martin S, Chamova T, et al.
Brain : a journal of neurology 2017; (140(2)):287-305 doi:10.1093/brain/aww307.
PMID: 28137957 - 2
Psychiatric Manifestations of ATP13A2 Mutations.
Balint B, Damasio J, Magrinelli F, et al.
Movement disorders clinical practice 2020; (7(7)):838-841 doi:10.1002/mdc3.13034.
PMID: 33033738 - 3
Pallidal degenerations and related disorders: an update.
Jellinger KA
Journal of neural transmission (Vienna, Austria : 1996) 2022; (129(5-6)):521-543 doi:10.1007/s00702-021-02392-2.
PMID: 34363531 - 4
Kufor-Rakeb syndrome: a cohort-based clinical, imaging and genetic profile.
Roy S, Mahale RR
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(1)):106.
PMID: 41493629 - 5
Experience in the clinical and genetic diagnosis of a series of Algerian patients with hereditary spastic paraplegias.
Messaoud-Khelifi M, Boulariah-Hadjou R, Kediha MI, et al.
Neurogenetics 2025; (26(1)):52 doi:10.1007/s10048-025-00833-8.
PMID: 40560206 - 6
[Psychopathological disorders at the onset of juvenile parkinsonism in childhood].
Goryunova AV, Shevchenko YS, Danilova LY, et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2024; (124(11. Vyp. 2)):96-102 doi:10.17116/jnevro202412411296.
PMID: 39576167 - 7
French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.
Mania-Pâris L, Ewenczyk C, Nicolas G, et al.
Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.
PMID: 40450402 - 8
Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
Pietrzak A, Badura-Stronka M, Kangas-Kontio T, et al.
Folia neuropathologica 2019; (57(3)):285-294 doi:10.5114/fn.2019.88459.
PMID: 31588715 - 9
A novel ATP13A2 variant causing complicated hereditary spastic paraplegia.
Zhang F, Liu P, Li J, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(4)):1749-1753 doi:10.1007/s10072-024-07334-w.
PMID: 38252374 - 10
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
Mole SE, Schulz A, Badoe E, et al.
Orphanet journal of rare diseases 2021; (16(1)):185 doi:10.1186/s13023-021-01813-5.
PMID: 33882967 - 11
Kufor-Rakeb Syndrome in a Guatemalan Patient With an ATP13A2 Gene Pathogenic Variant: A Case Report.
Méndez-Veras R, Urbizo A, Cabrera J, Boburg S
Case reports in genetics 2025; (2025()):6993134 doi:10.1155/crig/6993134.
PMID: 41306646 - 12
Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa-Responsive Parkinsonism Due to ATP13A2 Mutation.
Chien HF, Rodriguez RD, Bonifati V, et al.
Neurology 2021; (97(16)):763-766 doi:10.1212/WNL.0000000000012705.
PMID: 34475127
This page is for informational purposes only and does not constitute medical advice about CLN12 disease. Your neurologist, geneticist, and care team can recommend specialists and follow-up based on your symptoms and genetic findings.